Search





Search





Markets
/
Stocks
/
nasdaq-rnac
/

Cartesian Therapeutics Inc

RNAC

Add to Watchlist

7.380USD

-0.890-10.76%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

216.84MMarket Cap

LossP/E TTM



Cartesian Therapeutics Inc

7.380

-0.890-10.76%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cartesian Therapeutics Inc

Currency: USD Updated: 2026-05-15

Key Insights

Cartesian Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 131 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.17.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cartesian Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

131 / 382

Overall Ranking

258 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Cartesian Therapeutics Inc Highlights

StrengthsRisks

Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.80M.

Fairly Valued

The company’s latest PE is -1.27, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 7.99M shares, increasing 7.37% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 925.00 shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

34.167

Target Price

+313.14%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Cartesian Therapeutics Inc is 6.62, ranking 221 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 78.00K, representing a year-over-year decrease of 92.91%, while its net profit experienced a year-over-year decrease of 121.24%.

Score

Industry at a Glance

Previous score

6.62

Change



Financials

5.83

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.11

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.95

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.76

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.47

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cartesian Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Cartesian Therapeutics Inc is 6.20, ranking 303 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.27, which is -18307.24% below the recent high of 232.00 and -25547.26% above the recent low of -326.80.

Score

Industry at a Glance

Previous score

6.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 131/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Cartesian Therapeutics Inc is 8.22, ranking 152 out of 382 in the Biotechnology & Medical Research industry. The average price target is 39.00, with a high of 44.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.44

Change

-0.22

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

34.167

Target Price

+313.14%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Cartesian Therapeutics Inc

RNAC

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Cartesian Therapeutics Inc is 6.82, ranking 146 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.15 and the support level at 5.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.44

Change

-1.62

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.124

Buy

RSI(14)

49.913

Neutral

STOCH(KDJ)(9,3,3)

47.062

Sell

ATR(14)

0.610

High Vlolatility

CCI(14)

2.664

Neutral

Williams %R

57.630

Sell

TRIX(12,20)

1.110

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

8.260

Sell

MA10

8.077

Sell

MA20

7.402

Sell

MA50

6.970

Buy

MA100

7.050

Buy

MA200

8.149

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Cartesian Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 27.21%, representing a quarter-over-quarter increase of 9.60%. The largest institutional shareholder is James Simons, holding a total of 67.30K shares, representing 0.23% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Springer Timothy A

8.64M

+0.03%

Seven One Eight Three Four Irrevocable Trust

4.56M

Squarepoint Capital LLP

2.21M

+12032.00%

Fidelity Management & Research Company LLC

1.37M

-36.59%

Singer (Michael S.)

683.10K

-0.95%

TAS Partners, L.L.C.

656.51K

+23.92%

BlackRock Institutional Trust Company, N.A.

554.24K

-4.00%

Kalayoglu (Murat)

505.02K

+0.52%

Lu (Chafen)

330.69K

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cartesian Therapeutics Inc is 2.39, ranking 219 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.65. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.